SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by a low-float setup and intense short-squeeze dynamics that have captured the attention of retail traders. The community is actively debating the stock's long-term sustainability against its history of reverse splits and high borrowing costs, while many speculate about the potential for further explosive gains.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of recent delivery numbers and the launch of the new L80 model against a backdrop of ongoing short-seller activity. While some investors focus on strong year-over-year delivery growth and infrastructure expansion, others remain critical of the stock's performance and perceived manipulation by market makers.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing a high-volatility "sell the news" reaction despite delivering a record-breaking earnings beat and issuing bullish guidance that underscores sustained AI-driven demand. While the community is debating whether this dip offers a strategic buying opportunity or confirms a long-overdue valuation cooling after a historic year-long rally, many investors are focused on the company's aggressive share buyback plan as a potential defensive catalyst.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to the announcement of a multi-million dollar milestone payment from its partnership with Boehringer Ingelheim, which has triggered heightened trader interest ahead of an R&D Day presentation. Community sentiment is mixed, with some traders optimistic about the non-dilutive capital and autoimmune pipeline potential, while others remain cautious due to concerns over potential share dilution and a pending reverse stock split.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging after delivering a strong quarterly earnings beat, fueling investor optimism that the enterprise software sector may be bottoming out. The community is actively debating if this performance signals a broader recovery for SaaS companies or if it remains a tactical bounce amid ongoing concerns over AI-driven disruption.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing heightened community discussion as investors weigh the impact of new capital partnerships against broader sector volatility and bearish sentiment surrounding fintech. While some market participants anticipate a potential short squeeze, others remain cautious as the stock grapples with macroeconomic headwinds and lingering uncertainty regarding the company's performance in a high-rate environment.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring escalating geopolitical tensions in the Strait of Hormuz and a shifting conflict status with Iran, which is driving significant volatility and concerns over energy supply stability. The community is actively debating whether current stock market highs are sustainable in the face of these rising oil prices, Fed policy uncertainty, and mixed earnings reports.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting significant community attention due to its status as a low-float stock experiencing intense volatility, with retail investors closely monitoring for a potential short squeeze amid rumors of strategic acquisitions. Community sentiment is deeply polarized, with active debates centered on the company's long-term viability, upcoming delisting concerns, and the high-conviction participation of retail traders hoping to replicate past momentum spikes.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is trending as traders closely monitor its role as a leveraged Bitcoin proxy, with community discussion currently polarized between optimism over institutional accumulation and concerns regarding structural dilution. Investors remain focused on how the company's treasury strategy and dividend structure will perform in relation to broader Bitcoin price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of...

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence...

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, MarketBeat...

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual...

NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.

Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research report on Wednesday...

NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday...

Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026

NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.23	--	--	N/A
Q4 '25	-$0.16	-$0.08	48.77%	BEAT
Q3 '25	-$0.20	-$0.11	43.67%	BEAT
Q2 '25	-$0.22	-$0.26	-16.63%	MISSED
Q1 '25	-$0.24	-$0.21	12.81%	BEAT

NPCE
NeuroPace Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest NPCE News

NPCENeuroPace Inc